Brief: Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease

Sage Therapeutics

08/10/2024 11:43

Oct 8 (Reuters) - SAGE Therapeutics Inc  SAGE.O :
    * SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE
2
LIGHTWAVE STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF
MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA IN ALZHEIMER’S
DISEAS
    * SAGE THERAPEUTICS INC - DALZANEMDOR DID NOT SHOW
STATISTICALLY
SIGNIFICANT DIFFERENCE IN PHASE 2 STUDY
    * SAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY
WELL-TOLERATED, NO
NEW SAFETY SIGNALS OBSERVED
    * SAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF
DALZANEMDOR IN AD
    * SAGE THERAPEUTICS INC - TOPLINE DATA FROM PHASE 2
DIMENSION
STUDY EXPECTED LATER THIS YEAR

Source text for Eikon:  ID:nBw3CnWfRa 
Further company coverage:  SAGE.O 

 ((Reuters.Briefs@thomsonreuters.com;))